TITLE

Study Confirms Safety/Tolerability of Zaleplon for Insomia

PUB. DATE
November 1999
SOURCE
Worldwide Biotech;Nov99, Vol. 11 Issue 11, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Provides information on the result of a clinical trial on zaleplon, a medication for the long-term treatment of insomnia.
ACCESSION #
2435868

 

Related Articles

  • Zaleplon (ZAL-e-Plon).  // Drug Topics;12/6/99, Vol. 143 Issue 23, p44 

    Presents information about Zaleplon, a drug used in the treatment of insomnia. Includes brand name; Contraindications; Considerations when taking the drug; Side effects.

  • Sleep Problems In Early Childhood May Predict Substance Use During Adolescence. Wong, Maria M.; Brower, Kirk J.; Fitzgerald, Hiram E.; Zucker, Robert A. // Pediatrics for Parents;2004, Vol. 21 Issue 6, p7 

    The article focuses on insomnia and drug abuse in adolescents.

  • Zaleplon: A Review of its Use in the Treatment of Insomnia. Dooley, M.; Plosker, G.L. // Drugs;Aug2000, Vol. 60 Issue 2, p413 

    Zaleplon is a pyrazolopyrimidine hypnotic agent which is indicated for the short term (2 to 4 weeks) management of insomnia. Zaleplon 5 and 10mg at bedtime (usual recommended doses) significantly reduced sleep latency compared with placebo in clinical trials in nonelderly and elderly patients...

  • Eszopiclone. Mack, Alicia; Salazar, J. Octavio // Formulary;Oct2003, Vol. 38 Issue 10, p582 

    Provides information on the novel cyclopyrrolone eszopiclone, a stereoselective isomer of the agent zoplicone, used for the treatment of insomnia. Management of both transient and chronic insomnia with minimal side effects; Issue whether to make the drug openly available or through prior...

  • Enoxacin.  // Reactions Weekly;8/14/2010, Issue 1314, p18 

    The article describes the case of a 36-year-old woman who acquired insomnia, irritability and illusions following intravenous administration of enoxacin.

  • Edluar for insomnia.  // Monthly Prescribing Reference;Oct2009, Vol. 25 Issue 10, pA16 

    The article offers information on the availability of Edluar from Meda Pharmaceuticals Inc. for the short-term treatment of insomnia.

  • FDA Drug Approvals. New indication.  // Formulary;Feb2012, Vol. 47 Issue 2, p45 

    The article reports on a November 23, 2011 decision which the U.S. Food and Drug Administration made to approve the drug zolpidem tartrate for the treatment of insomnia which features middle-of-the-night waking. Research which the administration conducted on the drug to evaluate its safety,...

  • Methadone withdrawal.  // Reactions Weekly;5/29/2010, Issue 1303, p24 

    The article describes the case of a 33-year-old man who developed insomnia, pain and other withdrawal symptoms after stopping methadone treatment.

  • Melatonin Prolonged Release: In the Treatment of Insomnia in Patients Aged ≥55 years. Lyseng-Williamson, Katherine A. // Drugs & Aging;2012, Vol. 29 Issue 11, p911 

    Abstract Melatonin prolonged release (PR) 2 mg is approved for the treatment of primary insomnia characterized by poor sleep quality in patients aged ≥55 years in the EU and elsewhere. Patients may receive treatment with melatonin PR for up to 13 weeks. Production of endogenous nocturnal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics